News & media

September 11, 2018
Casma Therapeutics Announces Partnership with Fondazione Telethon, Founder of the Telethon Institute of Genetics and Medicine (TIGEM)

CAMBRIDGE, Mass., September 11, 2018 — Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced a research collaboration with Fondazione Telethon, founder of the Telethon Institute of Genetics and Medicine (TIGEM), to develop new therapies for lysosomal storage disorders and more common disorders such as neurodegeneration. TIGEM, an international research […]

August 6, 2018
Casma Therapeutics Expands Executive Team with Appointment of Two Senior Vice Presidents

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Casma Therapeutics, Inc., today announced the appointment of two executives with extensive experience in drug discovery and translational medicine to further the company’s goal of leveraging the natural cellular process of autophagy to treat neurodegenerative, inflammatory and lysosomal storage disorders, among other conditions. Jeffrey Saunders, Ph.D., Casma’s new senior vice president of drug […]

Investors and Media | May 30, 2018
Casma Therapeutics Co-Founder Reports Health Benefits of Increased Autophagy in Mammals in Nature Publication

CAMBRIDGE, Mass., May 30, 2018 — Casma Therapeutics Inc., a biotechnology company harnessing the natural cellular process of autophagy to design powerful new medicines, today announced the publication of a landmark paper by scientific co-founder Beth Levine describing the health and lifespan benefits of increased autophagy in a mouse model. The study, published in Nature, describes observations […]

Investors and Media, George Washington | May 3, 2018
Third Rock Ventures Launches Casma Therapeutics with $58.5 Million Investment to Harness the Cellular Process of Autophagy to Develop Breakthrough Therapies

Company is focusing on lysosomal storage disorders, liver and muscle diseases, inflammation and neurodegeneration CAMBRIDGE, Mass., May 3, 2018 — Casma Therapeutics, Inc., a biotechnology company harnessing the natural cellular process of autophagy to design powerful new medicines, launched today with $58.5 million in Series A funding from Third Rock Ventures. Casma is pioneering novel strategies […]

Page 3 of 3